Patrick C Souverein1, Ellen S Koster2, Gene Colice3, Eric van Ganse4, Alison Chisholm5, David Price6, Alexandra L Dima7. 1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Electronic address: P.C.Souverein@uu.nl. 2. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. 3. Global Medicines Development, AstraZeneca, Gaithersburg, Md. 4. Pharmaco-Epidemiology Lyon, HESPER, Claude Bernard University, Lyon, France; Respiratory Medicine, Croix-Rousse University Hospital, Lyon, France. 5. Respiratory Effectiveness Group, Cambridge, United Kingdom. 6. Respiratory Effectiveness Group, Cambridge, United Kingdom; Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. 7. Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Electronic prescribing records can enable exploration of medication adherence, but analysis decisions may influence estimates and require alignment to new consensus-based definitions. OBJECTIVE: To compare different computations of inhaled corticosteroid (ICS) implementation in a primary care asthma population initiating ICS therapy when assessed within episodes of persistent use, and examine longitudinal variation in implementation. METHODS: A historical cohort study was conducted on UK's Optimum Patient Care Research Database. Eligible patients had physician-diagnosed asthma, initiated ICS therapy, and had 3 or more years of continuous registration. ICS treatment episodes were constructed on the basis of 3 definitions, permitting 30-, 90-, and 182-day gaps between prescriptions. Implementation was estimated using 2 continuous medication availability (CMA I and II) definitions to explore effects of carryover of previous prescriptions in 4 observation windows: 6, 8, 12, and 24 months. Impact of methodology was assessed by descriptive statistics, linear mixed models, and measures of agreement. RESULTS: A total of 13,922 eligible patients (mean age, 39.9 years; 48.7% men) were identified. For CMA I, permitting a 90-day gap, mean ICS implementation for the 2-year period was 89.3% (±16.0%; range, 14.4%-100%). Sensitivity analyses with 30- and 182-day gaps resulted in increased (97.0% ± 7.2%) and decreased (81.1% ± 21.6%) estimates. CMA II produced estimates with varying concordance (0.69-0.87). Substantial variance was found between and within patients (intraclass coefficient, 0.30-0.36). CONCLUSIONS: Different analysis choices resulted in substantial variation in implementation estimates, highlighting the need for transparent and clinically relevant methododology. Distinguishing between (non)persistence and implementation is important in clinical practice, and may require different interventions in routine consultations.
BACKGROUND: Electronic prescribing records can enable exploration of medication adherence, but analysis decisions may influence estimates and require alignment to new consensus-based definitions. OBJECTIVE: To compare different computations of inhaled corticosteroid (ICS) implementation in a primary care asthma population initiating ICS therapy when assessed within episodes of persistent use, and examine longitudinal variation in implementation. METHODS: A historical cohort study was conducted on UK's Optimum Patient Care Research Database. Eligible patients had physician-diagnosed asthma, initiated ICS therapy, and had 3 or more years of continuous registration. ICS treatment episodes were constructed on the basis of 3 definitions, permitting 30-, 90-, and 182-day gaps between prescriptions. Implementation was estimated using 2 continuous medication availability (CMA I and II) definitions to explore effects of carryover of previous prescriptions in 4 observation windows: 6, 8, 12, and 24 months. Impact of methodology was assessed by descriptive statistics, linear mixed models, and measures of agreement. RESULTS: A total of 13,922 eligible patients (mean age, 39.9 years; 48.7% men) were identified. For CMA I, permitting a 90-day gap, mean ICS implementation for the 2-year period was 89.3% (±16.0%; range, 14.4%-100%). Sensitivity analyses with 30- and 182-day gaps resulted in increased (97.0% ± 7.2%) and decreased (81.1% ± 21.6%) estimates. CMA II produced estimates with varying concordance (0.69-0.87). Substantial variance was found between and within patients (intraclass coefficient, 0.30-0.36). CONCLUSIONS: Different analysis choices resulted in substantial variation in implementation estimates, highlighting the need for transparent and clinically relevant methododology. Distinguishing between (non)persistence and implementation is important in clinical practice, and may require different interventions in routine consultations.
Authors: Kimberly J Arcoleo; Colleen McGovern; Karenjot Kaur; Jill S Halterman; Jennifer Mammen; Hugh Crean; Deepa Rastogi; Jonathan M Feldman Journal: Ann Am Thorac Soc Date: 2019-06
Authors: Bright I Nwaru; Colin R Simpson; Ireneous N Soyiri; Rebecca Pillinger; Francis Appiagyei; Dermot Ryan; Hilary Critchley; David B Price; Catherine M Hawrylowicz; Aziz Sheikh Journal: BMJ Open Date: 2018-06-27 Impact factor: 2.692
Authors: Iida Vähätalo; Pinja Ilmarinen; Leena E Tuomisto; Minna Tommola; Onni Niemelä; Lauri Lehtimäki; Pentti Nieminen; Hannu Kankaanranta Journal: ERJ Open Res Date: 2020-03-23
Authors: Pascal C Baumgartner; Bernard Vrijens; Samuel Allemann; Kurt E Hersberger; Isabelle Arnet Journal: Pharmaceutics Date: 2022-01-02 Impact factor: 6.321